Further studies must be addressed in preclinical models of tau deposition to clarify the role of the endogenous cannabinoid system in AD, where both Aβ accumulation and tau deposition contribute to the loss of neurons and, subsequently, to the devastating dementia characterizing the disease. This evidence concerns the gene MAPT and Alzheimer disease.